SL-49. SMO inhibitors

ASINEX
Signature Libraries

The aberrant Hedgehog signaling pathway is implicated in the pathogenesis of several solid and hematologic tumors; moreover, this pathway plays a key role in the maintenance and differentiation of cancer stem cells (CSCs) which are hypothesized to be responsible for the emergence of drug resistance, disease progression, and metastasis. Smoothened (SMO) is a GPCR-like protein that positively regulates Hedgehog signaling and its mutations can lead to unregulated activation of the pathway and eventually to cancer. Several SMO inhibitors are in clinical development [1,2]. In 2012, first-in-class SMO inhibitor Vismodegib (Genetech) was approved by the US Food and Drug Administration for the treatment of basal-cell carcinoma; in 2015 Sonidegib (Novartis) was approved. Using a proprietary computational algorithm ASINEX has designed a library of small molecules sharing high structural similarity with approved drugs making them an interesting starting point for SMO-oriented drug discovery and research

.



Signature Library 49

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 µmol; 1 µmol DMSO solutions	SL#49_SMO inhibitors.sdf

References:

1. Nature medicine, 2013, 19, 11, 1410-1422 doi: 10.1038/nm.3389
2. OncoTargets and Therapy 2012, 5, 47-58, doi: https://dx.doi.org/10.2147/OTT.S21957

Contact us:
USA: +1 336 721 1617 mparisi@asinex.com
Japan: +81-80-3401-9097 sota@asinex.com
Europe/Global: lsadovenko@asinex.com